July 23, 2008 - EKOS Corp.’s EkoSonic Endovascular System (EkoSonic ES) with Rapid Pulse Modulation (RPM) for the dissolution of vascular blood clots, reportedly represents the only endovascular system that can deliver microsonic energy and thrombolytic drugs simultaneously, providing a safer, faster and more complete way to remove clots by accelerating dissolution.
Intermittent bursts of microsonic energy are said to effectively increase the permeability of the clot to the thrombolytic – four times faster than conventional catheter-directed thrombolysis with no evidence of thrombus breakage or hemolysis, EKOS said.
In addition to its RPM technology, EkoSonic ES includes an advanced control unit designed with an easier, more intuitive user interface, for simpler set up and operation. EkoSonic ES is also compatible with the EkoSonic Mach 4 Endovascular Device, (Mach 4), which offers a variety of treatment zone options.
Each Mach 4 consists of a MicroSonic Core within an Intelligent Drug Delivery Catheter. This combination device enables the system to deliver microsonic energy and drugs simultaneously to accelerate clot dissolution. Reduction in time translates to fewer drugs, lowering the risk profile of the procedure while the convergence of technologies results in a safer, faster, more complete outcome in the treatment of Deep Vein Thrombosis (DVT) and Peripheral Arterial Occlusions (PAO).
Over the past three years, physicians have responded favorably after performing nearly 6,000 cases utilizing the EKOS technology, the company said. Major U.S. medical centers utilizing the EkoSonic ES include Baptist Cardiac & Vascular Institute (Miami, FL), Cleveland Clinic Foundation (Cleveland, OH), Dartmouth-Hitchcock Medical Center (Lebanon, NH), Emory University Hospital (Atlanta, GA), Massachusetts General Hospital (Boston, MA), The Methodist Hospital (Houston, TX), University of Illinois Medical Center at Chicago (Chicago, IL), and the Swedish Medical Center (Seattle, WA).
For more information: www.ekoscorp.com